AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference
AtriCure (Nasdaq: ATRC), a leader in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Canaccord Genuity 44th Annual Global Growth Conference. The company's management is set to present on Tuesday, August 13, 2024, at 10:30 am EST.
Investors and interested parties can access a live audio webcast of the presentation through the 'Investors' section of AtriCure's website at https://ir.atricure.com. This event provides an opportunity for AtriCure to showcase its innovations and growth strategies to a global audience of investors and industry professionals.
AtriCure (Nasdaq: ATRC), un leader nei trattamenti chirurgici per fibrillazione atriale, gestione dell'appendice atriale sinistra e gestione del dolore post-operatorio, ha annunciato la sua partecipazione alla 44esima Conferenza Annuale di Crescita Globale di Canaccord Genuity. La direzione dell'azienda presenterà martedì 13 agosto 2024, alle 10:30 EST.
Investitori e parti interessate possono accedere a un webcast audio in diretta della presentazione attraverso la sezione 'Investitori' del sito web di AtriCure all'indirizzo https://ir.atricure.com. Questo evento rappresenta un'opportunità per AtriCure di mostrare le proprie innovazioni e strategie di crescita a un pubblico globale di investitori e professionisti del settore.
AtriCure (Nasdaq: ATRC), un líder en tratamientos quirúrgicos para fibrilación auricular, gestión del apéndice auricular izquierdo y gestión del dolor postoperatorio, ha anunciado su participación en la 44ª Conferencia Anual de Crecimiento Global de Canaccord Genuity. La dirección de la empresa presentará el martes 13 de agosto de 2024, a las 10:30 am EST.
Los inversores y partes interesadas pueden acceder a un webcast de audio en vivo de la presentación a través de la sección 'Inversores' del sitio web de AtriCure en https://ir.atricure.com. Este evento brinda la oportunidad a AtriCure de mostrar sus innovaciones y estrategias de crecimiento a una audiencia global de inversores y profesionales de la industria.
AtriCure (Nasdaq: ATRC)는 심방세동, 좌심방 부속기 관리 및 수술 후 통증 관리를 위한 수술 치료의 선두주자로, Canaccord Genuity 제44회 연례 글로벌 성장 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 8월 13일 화요일 오전 10시 30분 EST에 발표할 예정입니다.
투자자 및 이해 관계자는 AtriCure 웹사이트의 '투자자' 섹션을 통해 생중계 오디오 웹캐스트에 접속할 수 있습니다. 이 행사는 AtriCure가 혁신과 성장 전략을 세계의 투자자 및 업계 전문가들에게 선보일 기회를 제공합니다.
AtriCure (Nasdaq: ATRC), un leader dans les traitements chirurgicaux de la fibrillation auriculaire, de la gestion de l'appendice auriculaire gauche et de la gestion de la douleur post-opératoire, a annoncé sa participation à la 44ème Conférence Annuelle de Croissance Globale de Canaccord Genuity. La direction de l'entreprise est prévue de présenter le mardi 13 août 2024 à 10h30 EST.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire audio en direct de la présentation via la section 'Investisseurs' du site internet d'AtriCure à l'adresse https://ir.atricure.com. Cet événement offre à AtriCure l'occasion de présenter ses innovations et stratégies de croissance à un public mondial d'investisseurs et de professionnels de l'industrie.
AtriCure (Nasdaq: ATRC), ein führendes Unternehmen im Bereich chirurgischer Behandlungen von Vorhofflimmern, Management des linken Vorhofanhangs und postoperativer Schmerzbewirtschaftung, hat seine Teilnahme an der 44. jährlichen Global Growth Conference von Canaccord Genuity bekannt gegeben. Das Management des Unternehmens wird am Dienstag, den 13. August 2024, um 10:30 Uhr EST präsentieren.
Investoren und Interessierte können über den Bereich 'Investoren' auf der Website von AtriCure auf ein live Audio-Webcast der Präsentation zugreifen unter https://ir.atricure.com. Diese Veranstaltung bietet AtriCure die Gelegenheit, seine Innovationen und Wachstumsstrategien einem globalen Publikum von Investoren und Fachleuten der Branche vorzustellen.
- None.
- None.
AtriCure’s management is scheduled to present on Tuesday, August 13, 2024, at 10:30 am EST. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240729478732/en/
Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
awirick@atricure.com
Marissa Bych
Gilmartin Group
Investor Relations
marissa@gilmartinir.com
Source: AtriCure, Inc.
FAQ
When is AtriCure (ATRC) presenting at the Canaccord Genuity Global Growth Conference?
How can I access AtriCure's (ATRC) presentation at the Canaccord Genuity conference?
What are the main areas of focus for AtriCure (ATRC)?
Which stock exchange is AtriCure (ATRC) listed on?
